alexa Long-Term Effectiveness of First-Line Antiretroviral Th
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Long-Term Effectiveness of First-Line Antiretroviral Theraphy in a Cohort of HIV-1 Infected Patients

Jordi Navarro-Mercadé1*, Manuel Crespo1, Vicenç Falcó1, Eva Van Den Eynde1, Adrian Curran1, Joaquín Burgos1, Sara Villar Del Saz1, Estrella Caballero2, Imma Ocaña1, Mercè Perez-Bernal1, Esteban Ribera1 and Albert Pahissa1

1Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Infectious Diseases Service. Medicine Department, Spain

2Hospital Universitari Vall d’Hebron, Microbiology Service, Spain

*Corresponding Author:
Jordi Navarro-Mercadé
Servicio de Enfermedades Infecciosas
Paseo Vall d’Hebron 119-129
08035 Barcelona, Spain
Tel: 34-93-274-62-51
Fax: 34-93-489-40-91
E-mail: [email protected]

Received Date: March 06, 2012; Accepted Date: March 26, 2012; Published Date: March 28, 2012

Citation: Navarro-Mercadé J, Crespo M, Falcó V, Den Eynde EV, Curran A, et al. (2012) Long-Term Effectiveness of First-Line Antiretroviral Theraphy in a Cohort of HIV-1 Infected Patients. J Antivir Antiretrovir 4: 026-031. doi: 10.4172/jaa.1000042

Copyright: © 2012 Navarro-Mercadé J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Background: Eligibility criteria might explain differences in viral response to combined antiretroviral treatment (cART) between clinical trials and routine care setting. Our aim was to assess the effectiveness of cART and factors associated to therapeutic failure (TF) in real clinical conditions.
Methods: A prospective cohort analysis including HIV-1 infected patients who started a cART between January 2004 and December 2009, at Vall d’Hebron Hospital. Effectiveness was evaluated as time to TF defined as the first of either virologic failure, treatment discontinuation whatever the reason other than switching, loss to follow-up, or death. The Kaplan-Meier method was used to estimate time-to-event distributions and Cox regression modelling to identify factors associated with TF.
Results: We analyzed 232 patients; median CD4+ cell count was 229 cells/mm3 and median viral load 4.89 log10. Almost a third of patients was co-infected with HCV and/or HBV. Tenofovir plus lamivudine/emtricitabine (67%) was the commonest backbone, and efavirenz (77%) the preferred third drug. The proportion of patients with no TF at month 12, 24 and 36 was 82.9%, 78.5% and 76% respectively. TF occurred in 57 (24.6%) patients, mainly due to intolerance or toxicity. The risk of TF was higher in patients starting cART before 2006 and in those with a protease inhibitor based regimen.
Conclusions: After a median follow-up of 36.5 months, three-fourth of patients who started first-line cART remained free of TF. Treatment discontinuation stands as the leading cause of TF.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version